Eocene Ltd. (EOCN)
Snapshot
- 1 week
- +6.3%+6.7% vs SPY
- 1 month
- -16.3%-15.3% vs SPY
- Market cap
- $3.2M
- Short % float
- 1.4%
- Days to cover
- 2.0
- Short change
- +26.2%
Signal evidence
Prediction markets
Kalshi · Polymarket · … linked
Company
Eocene Ltd. (EOCN). Eocene Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquart…
- Allen BaharaffCo-Founder, President, CEO & ChairmanUSD 1.6M
- Yohai StenzlerChief Accounting OfficerUSD 341K
- Guy NehemyaCOO & Data Protection OfficerUSD 334K
- Doron CohenChief Financial OfficerUSD 287K
- Tali GorfineMedical ConsultantUSD 203K
- Liat HayardenyChief Scientific Officer
Snapshot
Price & returns1 month -16.3%
- 1 week
- +6.3%+6.7% vs SPY
- 1 month
- -16.3%-15.3% vs SPY
Valuationmarket cap $3.2M
- Market cap
- $3.2M
Short interest & optionsshort 1.4% of float
- Short % float
- 1.4%
- Days to cover
- 2.0
- Short change
- +26.2%
Signal evidence
Prediction markets
Kalshi · Polymarket · … linked
Company
Eocene Ltd. (EOCN). Eocene Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquart…
- Allen BaharaffCo-Founder, President, CEO & ChairmanUSD 1.6M
- Yohai StenzlerChief Accounting OfficerUSD 341K
- Guy NehemyaCOO & Data Protection OfficerUSD 334K
- Doron CohenChief Financial OfficerUSD 287K
Company news
Loading headlines…